Phase 2 N=100 Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Lymphoma
Primary: 2-year Progression-Free Survival (PFS) — 0.76; 0.42 probability
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=96 Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma
Non-Hodgkin's Lymphoma
Primary: 2-year PFS From the Start of Induction Therapy Conditional — 86.6; 90.6; 0.4 percentage of patients
Phase 2 N=67 Diffuse Large B Cell Non-Hodgkin's Lymphoma in the Vulnerable/Frail Elderly. A Multicentric Randomized Phase II Trial
Lymphoma
Primary: Number of Participants in Complete Remission 6 Months After Randomization — 14; 9 Participants
Phase 2 N=47 Safety and Efficacy of Blinatumomab in Adults With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma
High-risk Diffuse Large B-Cell Lymphoma
Primary: Participants With Treatment-Emergent (Blinatumomab) Adverse Events — 28; 11; 5; 7 Participants
Phase 2 N=73 Combination Chemo, Rituximab, and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma
Contiguous Stage II Adult Diffuse Large Cell Lymphoma · Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma · Stage III Adult Diffuse Large Cell Lymphoma
Primary: Progression-free Survival at 1 Year — 77 percentage of participants
Phase 2 N=138 Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma
Lymphoma
Primary: Toxicity as Assessed by NCI CTCAE v3.0 (Phase I) — 3; 3; 5; 2 Participants
Phase 2 N=107 Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
Lymphoma
Primary: Event-free Survival After 12 Months — 78 percentage of participants
Phase 2 N=50 Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas
Hodgkin Lymphoma · Diffuse Large B-Cell Lymphoma
Primary: Progression Free Survival (PFS) — 6.6 months
Phase 3 N=742 Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Diffuse Large B-cell Lymphoma
Primary: Disease-free Survival (DFS) — 77.8; 77.0 Percentage of participants — p=0.276
Phase 2 N=159 S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma
Lymphoma
Primary: Five-year Progression-free Survival (PFS) Rate in Patients With Newly Diagnosed Limited Stage Diffuse Large B-cell Lymphoma (DLBCL) — 87 percentage of participants
Phase 2 N=194 Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma
Burkitt Lymphoma · Diffuse Large B-cell Lymphoma, c-MYC Positive · Plasmablastic Lymphoma
Primary: Percentage of Participants With Kaplan-Meier Curve Progression Free Survival (PFS) Constructed With an 95% Confidence Interval — 100; 82.1; 71.0 percentage of participants
Phase 2 N=48 Trial on Lenalidomide Given as Maintenance Therapy for Relapsed Diffuse Large B Cell Lymphoma
Diffuse Large B-cell Lymphoma
Primary: 1-year Progression-free Survival — 31 Participants
Phase 2 N=80 Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma
Lymphoma
Primary: Disease Response (Complete, Complete Unconfirmed, and Partial Responses) After 4 Courses — 47; 8; 14 Participants
Phase 3 N=524 Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Large B Cell Lymphoma
Primary: Progression-Free Survival Rate at 2 and 5 Years — 78.9; 75.5; 68.0; 66.0 percentage of participants — p=0.6519
Phase 2 N=46 S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma
Lymphoma
Primary: Progression-free Survival — 89 percentage of participants
Phase 2 N=34 Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma
Hodgkin Lymphoma
Primary: Complete Response Rate — 34 Participants
Phase 2 N=30 Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma
Lymphoma
Primary: Event-free Survival — 76 percentage of patient
Phase 2 N=9 Phase 2 Study of Bexxar in Relapsed/Refractory DLCL
Lymphoma
Primary: Clinical Response Rate — 2; 0; 1; 1 participants
Phase 2 N=17 LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma
Non-Hodgkin's Lymphoma
Primary: Complete Remission — 10 participants
Phase 2 N=87 S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
Lymphoma
Primary: Percentage of Participants With 3-year Progression-free Survival (PFS) — 90 percentage of participants
Phase 2 N=25 Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Lymphoma
Primary: Response Rate = Complete and Partial Response at 12 Weeks. — 5; 3; 2; 15 participants
Phase 2 N=30 CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas
Non-Hodgkin Lymphoma · Mycosis Fungoides
Primary: Objective Response Rate (ORR) — 26.7; 35.7 percentage of treated subjects
Phase 2 N=35 Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Diffuse Large B Cell Lymphoma Relapsed · Diffuse Large B Cell Lymphoma Refractory
Primary: Number of Participants With Dose-Limiting Toxicities as a Measure of Safety and Tolerability — 0; 0; 0; 1 Participants
Phase 2 N=44 Lenalidomide With or Without Rituximab After Standard Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma
Lymphoma
Primary: Disease-free Survival at 1 Year — 0.818; 0.90 years
Phase 2 N=18 HM2014-26 DT2219 for Relapsed or Refractory B-Lineage Leukemia or Lymphoma
Refractory B-Lineage Leukemia · Relapsed B-Lineage Leukemia · Refractory B-Lineage Lymphoma
Primary: Phase I: Incidence of Any DLT Attributed to DT2219 in the First Cycle — 1; 3; 0 events
Phase 2 N=72 CT-011 MAb in DLBCL Patients Following ASCT
Lymphoma, Large Cell, Diffuse · Lymphoma, Mixed Cell, Diffuse · Primary Mediastinal Large B-Cell Lymphoma
Primary: Progression-free Survival — 72 Percent
Phase 2 N=86 S0433 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma
Lymphoma
Primary: Progression-free Survival (PFS) at 2 Years — 69 percentage of participants
Phase 2 N=19 Intensive Consolidation and Stem Cell Mobilization Therapy Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Diffuse Large Cell Lymphoma Relapsed/Refractory
Primary: Number of Patients Achieving Complete Response (CR) to the Treatment Upon Successful Stem Cell Mobilization — 10 Participants
Phase 2 N=35 Oral Panobinostat Adult Patients DLBCL Relapsed/Refractory Stem Cell Transfusion (ASCT) or Not Eligible for ASCT
Diffuse Large B-cell Lymphoma
Primary: Overall Response Rate (ORR) at the End of the Induction Phase — 17.1 percentage of participants
Phase 2 N=24 Rituximab and Denileukin Diftitox in Treating Patients With Previously Untreated Stage III or Stage IV Follicular B-Cell Non-Hodgkin's Lymphoma
Lymphoma
Primary: Proportion of Confirmed Tumor Response (Complete Response [CR], Unconfirmed CR, and Partial Response) — 0.48 proportion of participants